Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP lifted its stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 268.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,758 shares of the company’s stock after buying an additional 58,094 shares during the period. Marshall Wace LLP owned approximately 0.31% of Leap Therapeutics worth $156,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LPTX. Key Client Fiduciary Advisors LLC lifted its position in Leap Therapeutics by 8.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 233,018 shares of the company’s stock valued at $620,000 after purchasing an additional 18,408 shares during the period. Acadian Asset Management LLC lifted its position in Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after purchasing an additional 219,563 shares during the period. Simplify Asset Management Inc. lifted its position in Leap Therapeutics by 67.9% during the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock valued at $1,237,000 after purchasing an additional 255,293 shares during the period. Finally, Vanguard Group Inc. lifted its position in Leap Therapeutics by 111.7% during the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after purchasing an additional 457,904 shares during the period. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LPTX has been the subject of a number of research reports. Rodman & Renshaw initiated coverage on shares of Leap Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $8.00 target price for the company. HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of Leap Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $10.40.

Leap Therapeutics Stock Performance

Shares of Leap Therapeutics stock opened at $2.31 on Monday. The firm has a 50-day simple moving average of $2.63 and a two-hundred day simple moving average of $2.52. The company has a market cap of $59.14 million, a P/E ratio of -0.97 and a beta of 0.27. Leap Therapeutics, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $5.00.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Equities research analysts forecast that Leap Therapeutics, Inc. will post -1.84 EPS for the current year.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.